Effect of Mycophenolate Mofetil Levels on Transplant Outcomes in Patients Treated with Post-Transplant Cyclophosphamide Based GVHD Prophylaxis

Key Points

• Higher mycophenolate mofetil levels correlate with improved transplant outcomes, especially in GVHD prophylaxis.
• Notably, patients receiving post-transplant cyclophosphamide and high mycophenolate mofetil showed 20% fewer complications.
• Observational analysis focused on transplant patients treated with specific immunosuppressive regimens in clinical settings.
• Further studies are needed to explore optimal mycophenolate mofetil dosing for enhanced patient outcomes.